An international study carried out with involvement of the MedUni Vienna is giving hope to patients with advanced prostate cancer.
In just a few years’ time, Ipilumumab could be approved as a treatment for the world’s third-most common type of cancer.
The immunotherapeutic agent Ipilumumab has been shown to have a markedly positive effect in the treatment of patients who are resistant to conventional hormone treatments and chemotherapy. These are the words of a core statement from a study, recently published in the highly respected journal “The Lancet Oncology”, which was set up based on collaboration between the world’s leading centres for the research and treatment of prostate cancer.
The scientists investigated the extent to which immunotherapy with this agent is also suitable for the more common type of advanced prostate cancer. The medication is already being successfully used as immunotherapy for advanced melanoma – a comparatively rare type of cancer.
Read more . . .
The Latest on: Immunotherapy
[google_news title=”” keyword=”Immunotherapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Immunotherapy
- Marion woman triumphs over colon cancer with advanced immunotherapy clinical trialon March 27, 2024 at 9:02 pm
A Marion woman is winning her fight against cancer thanks to a clinical treatment that doesn't require surgery and uses her immune system to detect and target c ...
- Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025on March 27, 2024 at 10:45 am
Full-year results and business update Lead program TG4050 to deliver data in 2024. Advancements in other clinical programs and Research and ...
- New immunotherapy could make blood more 'youthful,' mouse study hintson March 27, 2024 at 9:00 am
Scientists reversed some signs of immune aging in mice with a new treatment that could one day potentially be used in humans. The new immunotherapy works by disrupting a natural process by which the ...
- Borrowing an idea from cancer immunotherapy, scientists make old-mice immune systems youthful againon March 27, 2024 at 9:00 am
The Stanford lab of Irv Weissman channeled its cancer-targeting expertise to tip the immune systems of aged mice back to a youthful state.
- Purdue researchers create biocompatible nanoparticles to enhance systemic delivery of cancer immunotherapyon March 27, 2024 at 7:19 am
WEST LAFAYETTE, Ind. — Purdue University researchers are developing and validating patent-pending poly (lactic-co-glycolic acid), or PLGA, nanoparticles modified with adenosine triphosphate, or ATP, ...
- Lunit SCOPE IO Reveals Promising Results in Neoadjuvant Immunotherapy Study for Head and Neck Cancer Patientson March 26, 2024 at 6:55 pm
Lunit SCOPE IO analyzes the tumor microenvironment (TME) based on H&E analysis and provides AI-based predictive clinical outcome information. In addition, AI-driven Immunohistochemistry (IHC) slide ...
- Biocompatible nanoparticles enhance systemic delivery of cancer immunotherapyon March 26, 2024 at 5:00 pm
(Nanowerk News) Purdue University researchers are developing and validating patent-pending poly (lactic-co-glycolic acid), or PLGA, nanoparticles modified with adenosine triphosphate, or ATP, to ...
- Genetically engineered dendritic cells enhance the power of immunotherapy against lung canceron March 26, 2024 at 10:19 am
A study by researchers at the UCLA Health Jonsson Comprehensive Cancer Center suggests that injecting engineered dendritic cells directly into cancerous lung tumors can help promote a stronger immune ...
- Merck, Others Look to Immunotherapy Combos as Next Frontier in Oncologyon March 24, 2024 at 9:46 pm
Drugmakers are testing a variety of biologics and small molecules in conjunction with therapies aimed at modulating the immune system to target and destroy cancer cells.
- Bypassing oral immunotherapy buildup safe in children with food allergyon March 24, 2024 at 1:40 pm
An initial phase of multifood sublingual immunotherapy (SLIT) that bypasses oral immunotherapy (OIT) buildup is safe and effective, according to a study published online Feb. 27 in the Journal of ...
via Bing News